NCT02414347Recruiting
F 18 T807 Tau PET Imaging of Alzheimer's Disease
F 18 T807 Tau PET Imaging of Alzheimer's Disease [IND# 123119] Protocol A
Source: ClinicalTrials.gov · Last updated 8 Jun 2026
Brief summary (registry, in English)
A single-center, open-label baseline controlled imaging study designed to assess whether brain tau fibril uptake of flortaucipir as measured by PET correlates with cognitive status of individuals with and without brain tau fibrils.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 900 (estimated)
- First submitted
- 7 Apr 2015
- Start date
- 23 Oct 2014
- Primary completion date
- 31 Oct 2026
- Lead sponsor
- Tammie L. S. Benzinger, MD, PhD
- Diseases
- Alzheimer disease
- NCT number
- NCT02414347
What you commit to
- Study type: Observational
- Planned participants: 900
- From 23 Oct 2014 to the primary completion date, 31 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- For those electing to undergo the optional lumbar puncture: currently on anticoagulant of any form -
Other illness
- Has any condition that, in the Investigator's opinion, could increase risk to the participant, limit the participant's ability to tolerate the experimental procedures, or interfere with the collection/analysis of the data (for example, participants with severe chronic back pain might not be able to lie still during the scanning procedures).
- Has hypersensitivity to F 18 T807 or any of its excipients.
Lab values
- Has a high risk for Torsades de Pointes or is taking medications known to prolong QT interval.
Other
- Is deemed likely unable to perform the imaging procedures for any reason.
- Contraindications to PET, PET-CT or MR (e.g. electronic medical devices, inability to lie still for long periods) that make it unsafe for the individual to participate.
- Severe claustrophobia.
- Currently pregnant or breast-feeding.
Who the study is looking for
- Male or female participants, at least 18 years of age.
- Cognitively normal, or with mild dementia, as assessed clinically
- Participant is able and willing to undergo testing (MRI or CT, PET, radioactive tracer injection, LP; for those unable to undergo an MRI, CT will be used to generate regions-of-interest).
- Pre-menopausal women will undergo a urine pregnancy test within 24 hours of drug administration.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Washington University School of Medicine Coordinator of this site? Confirm its status | St Louis | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.